David Kallend
Chief Medical Officer, LIB Therapeutics, LLC · DalCor · LIB Therapeutics
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Kallend as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:33 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07102511 · Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHLIB Therapeutics LLC · enrolling by invitation · Familial Hypercholesterolemia - Heterozygous · study director
- Ph3NCT05918861 · Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACSDalCor Pharmaceuticals · recruiting · Acute Coronary Syndrome · study director
- Ph3NCT04797104 · Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C ReductionLIB Therapeutics LLC · completed · Heterozygous Familial Hypercholesterolemia · study director
- Ph3NCT04798430 · Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionLIB Therapeutics LLC · unknown · Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia · study director
- Ph2NCT04676867 · Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19DalCor Pharmaceuticals · completed · Covid19 · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:33 UTC. The ranking covers the 200 most relevant of 46 PubMed records, and a shared surname and initials can bring in a namesake. All 46 on PubMed
- Effects of dalcetrapib in patients with a recent acute coronary syndrome.N Engl J Med · 20121,669 citationsRCR 49.6
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.N Engl J Med · 20201,252 citationsRCR 57.5
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.N Engl J Med · 2017799 citationsRCR 27.7
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.N Engl J Med · 2020666 citationsRCR 30.7
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.N Engl J Med · 2017620 citationsRCR 20.8
- 439 citationsRCR 11.8
- Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.J Am Coll Cardiol · 2015219 citationsRCR 7.5
- Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.Eur Heart J · 2012183 citationsRCR 5.4
- Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.Am Heart J · 2009149 citationsRCR 3.5
- 147 citationsRCR 5.9